The owners of AMW GmbH are entering into an agreement to sell their shares in the specialty pharma company located in Warngau along with its subsidiary Endomedica GmbH located in Halle (Saale) to a consortium led by Hybio Pharmaceutical and YF capital. 

The new owners intend to support the further growth of AMW, invest in the development of new products, and advance the company’s internationalization efforts. The sellers include AMW founders, healthcare investor SHS Gesellschaft für Beteiligungsmanagement, funds managed by Bayern Kapital, KfW, IBG Risikokapitalfonds II, BayBG Bayerische Beteiligungsgesellschaft and UVC Partners.

Located in Warngau, Bavaria, AMW was established in 2008 with a focus on the development, production and sale of advanced pharmaceutical formulations such as transdermal drug delivery systems and subcutaneous biodegradable sustained-release implants. Transdermal and parenteral drug delivery systems offer better treatment options in a rapidly growing field of indications in oncology, neurology, dermatology, diabetes and pain treatment. 

The transaction is still pending formal approval of the regulatory authorities.
 

“Both Hybio and YF Capital intend to maintain and accelerate the growth of the company’s current structure including the transdermal and parenteral products, business sites in Warngau and Halle (Saale), as well as the skilled employees andmanagement team” says Dr. Albert Huang, vice president from YF Capital, “with the capacity of a financially strong strategic partners, we do believe that AMW can proceed to the next level in the pharma business, also we strongly believe the collaboration between AMW and Hybio will be highly beneficial for both parties, addressing global market growth opportunities.”

Dr. Wilfried Fischer, managing director of AMW, said, “the commitment of the new owner to the existing product pipeline as well as the willingness to make use of the technology to start new development projects perfectly matches AMW’s long-term strategy.”